Latest news with #MedibankPrivate
Business Insider
18 hours ago
- Business
- Business Insider
Morgan Stanley Keeps Their Hold Rating on Medibank Private (MDBPF)
Morgan Stanley analyst Andrei Stadnik maintained a Hold rating on Medibank Private (MDBPF – Research Report) today and set a price target of A$4.50. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Stadnik covers the Financial sector, focusing on stocks such as Macquarie Group Limited, QBE Insurance Group Limited, and Computershare Limited. According to TipRanks, Stadnik has an average return of 6.2% and a 55.76% success rate on recommended stocks. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Medibank Private with a $3.02 average price target.
Business Insider
3 days ago
- Business
- Business Insider
Macquarie Sticks to Their Hold Rating for Medibank Private (MDBPF)
In a report released today, Andrew Buncombe from Macquarie maintained a Hold rating on Medibank Private (MDBPF – Research Report), with a price target of A$4.25. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Buncombe covers the Financial sector, focusing on stocks such as Insurance Australia Group Limited, ASX , and NIB Holdings Ltd. According to TipRanks, Buncombe has an average return of 11.6% and a 78.43% success rate on recommended stocks. Currently, the analyst consensus on Medibank Private is a Moderate Buy with an average price target of $3.04.
Yahoo
21-05-2025
- Business
- Yahoo
Investors in Medibank Private (ASX:MPL) have seen solid returns of 106% over the past five years
Generally speaking the aim of active stock picking is to find companies that provide returns that are superior to the market average. And the truth is, you can make significant gains if you buy good quality businesses at the right price. For example, long term Medibank Private Limited (ASX:MPL) shareholders have enjoyed a 67% share price rise over the last half decade, well in excess of the market return of around 47% (not including dividends). On the other hand, the more recent gains haven't been so impressive, with shareholders gaining just 36%, including dividends. So let's investigate and see if the longer term performance of the company has been in line with the underlying business' progress. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. There is no denying that markets are sometimes efficient, but prices do not always reflect underlying business performance. One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS). During five years of share price growth, Medibank Private achieved compound earnings per share (EPS) growth of 3.0% per year. This EPS growth is slower than the share price growth of 11% per year, over the same period. This suggests that market participants hold the company in higher regard, these days. And that's hardly shocking given the track record of growth. The image below shows how EPS has tracked over time (if you click on the image you can see greater detail). We like that insiders have been buying shares in the last twelve months. Having said that, most people consider earnings and revenue growth trends to be a more meaningful guide to the business. Dive deeper into the earnings by checking this interactive graph of Medibank Private's earnings, revenue and cash flow. It is important to consider the total shareholder return, as well as the share price return, for any given stock. The TSR incorporates the value of any spin-offs or discounted capital raisings, along with any dividends, based on the assumption that the dividends are reinvested. So for companies that pay a generous dividend, the TSR is often a lot higher than the share price return. In the case of Medibank Private, it has a TSR of 106% for the last 5 years. That exceeds its share price return that we previously mentioned. This is largely a result of its dividend payments! We're pleased to report that Medibank Private shareholders have received a total shareholder return of 36% over one year. That's including the dividend. That gain is better than the annual TSR over five years, which is 16%. Therefore it seems like sentiment around the company has been positive lately. In the best case scenario, this may hint at some real business momentum, implying that now could be a great time to delve deeper. It's always interesting to track share price performance over the longer term. But to understand Medibank Private better, we need to consider many other factors. Consider risks, for instance. Every company has them, and we've spotted 1 warning sign for Medibank Private you should know about. Medibank Private is not the only stock that insiders are buying. For those who like to find lesser know companies this free list of growing companies with recent insider purchasing, could be just the ticket. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Australian exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
AU Financial Review
16-05-2025
- Health
- AU Financial Review
Australia moves towards a US-style health system - is that a good thing?
If you live in a capital Australian city and need to see a dentist or optometrist, there is a good chance you will end up in a clinic owned by your private health insurer. The same could be true for hospitals in the near future. Health funds such as Medibank Private, HCF, NIB and Bupa are investing hundreds of millions of dollars into primary care and telehealth. The move marks a significant shift in the healthcare model. Insurers have traditionally funded healthcare, but now they want to provide it as well.
Business Insider
12-05-2025
- Business
- Business Insider
Jarden Remains a Hold on Medibank Private (MDBPF)
In a report released today, Daniel Bui from Jarden maintained a Hold rating on Medibank Private (MDBPF – Research Report), with a price target of A$4.45. The company's shares closed last Thursday at $2.77. Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. Bui covers the Financial sector, focusing on stocks such as Challenger , AMP , and Computershare Limited. According to TipRanks, Bui has an average return of -1.6% and a 43.48% success rate on recommended stocks. Medibank Private has an analyst consensus of Moderate Buy, with a price target consensus of $2.98. MDBPF market cap is currently $8.32B and has a P/E ratio of 16.95.
